Posted Two Blokes
bySanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development per
Source: Two Blokes Trading
Posted Two Blokes
byBMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impact
Source: Two Blokes Trading
Posted Two Blokes
byThe S&P 500 edged higher on Wednesday, gaining 0.2% as it approached its all-time highs, buoyed by easing geop
Source: Two Blokes Trading
Posted Two Blokes
byPaychex (PAYX) was the worst-performing stock in the S&P 500 Wednesday after the payroll and human resources s
Source: Two Blokes Trading
Posted Two Blokes
by“Diversify to amplify” is the call from Goldman strategists.
Source: Two Blokes Trading
Posted Two Blokes
byPuma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pip
Source: Two Blokes Trading
Posted Two Blokes
byHighlights:
Source: Two Blokes Trading
Posted Two Blokes
byTesla's new car sales plummeted 27.9% in May from the year before, according to data from the European Automob
Source: Two Blokes Trading
Posted Two Blokes
byPaul Gruenwald, Chief Economist at S&P Global Ratings is forecasting global GDP growth at 2.9% in 2025, saying
Source: Two Blokes Trading
Posted Two Blokes
bySales of new single-family homes dropped 13.7% in May compared with April, according to the U.S. Census. Home
Source: Two Blokes Trading
Posted Two Blokes
byAnterix Inc. (NASDAQ:ATEX ) Q4 2025 Earnings Call June 25, 2025 9:00 AM ET Company Participants Christopher Gu
Source: Two Blokes Trading
Posted Two Blokes
byRoom for US Dollar (USD) to continue to edge lower against Chinese Yuan (CNH), but any decline is unlikely to
Source: Two Blokes Trading